หน้าแรก
ค้นหา
Tumor-immune interactions in triple negative breast cancer brain metastases
Maxine Umeh-Garcia, Stanford University, Neurosurgery Deptartment
แสดงข้อมูลเพิ่มเติม 1
Tumor-immune interactions in triple negative breast cancer brain metastases
Prognostic impact of immune interactions in patients with HER2+ and TNBC with brain metastases
Metastatic Triple-Negative Breast Cancer Ongoing Trials
Harnessing the Immune System in the Treatment of Triple-Negative Breast Cancer
Brain Metastases in Breast Cancer Risks of Developing Brain Metastasis in Breast Cancer
Overview of Brain Metastasis
Molecular Hallmarks of Tumor-Stromal Interactions in Brain Metastasis
It is Time for TIME (Tumor Immune Microenvironment) in Experimental and Diagnostic Pathology
Atezolizumab for TNBC
Gene expression profiling of breast cancer brain mets shows enrichment for non-luminal subtypes
Brain Metastases in Breast Cancer, Prognosis and Impact on Survival
Metastatic Triple Negative Breast Cancer Targeted Therapy Treatment Options and Potential Side Effe
Cancer Immune Checkpoint Inhibitors
Dr. Anders on Systemic Agents for Patients With Breast Cancer and Brain Mets
Understanding Tumor Heterogeneity and Cellular Plasticity as Key Drivers of Metastasis
What Is Metastatic Triple Negative Breast Cancer and The Outlook for Women Living with This Disease
Oncotarget: Sacituzumab Govitecan in Triple-Negative Breast Cancer
Brain Metastasis: A Cancer Neuroscience Perspective
Key clinical trials in breast cancer presented at SABCS 2021
Olaparib Alone or in Comb. w Atezolizumab in Treatment of Patients with HER2- BRCAmt Breast Cancer
